Literature DB >> 2993441

Interferon-induced 2'-5' oligoadenylate synthetase during interferon-alpha therapy in homosexual men with Kaposi's sarcoma: marked deficiency in biochemical response to interferon in patients with acquired immunodeficiency syndrome.

O T Preble, A H Rook, R Steis, R H Silverman, D Krause, G V Quinnan, H Masur, J Jacob, D Longo, E P Gelmann.   

Abstract

Titers of circulating interferon (IFN) and the activity of 2'-5' oligoadenylate (2-5A) synthetase, an enzyme specifically induced by IFN, were measured in 28 homosexual men with acquired immunodeficiency syndrome (AIDS) who received one- to six-month courses of antineoplastic therapy with IFN-alpha and in homosexual and heterosexual controls. Fifteen of the patients and two of seven healthy homosexual men had high endogenous levels of 2-5A synthetase. IFN therapy induced further increases in this enzyme in only 10 of the 28 patients with AIDS. Furthermore, peripheral blood cells from all but one of the patients with AIDS and homosexual controls tested were markedly deficient in their ability to respond to IFN in vitro, as measured by increased levels of 2-5A synthetase. We did not find a statistical correlation between cytomegalovirus viremia and pretherapy endogenous circulating IFN, nor any apparent correlation between disseminated infection with cytomegalovirus and either basal levels of 2-5A synthetase or changes in enzyme level during therapy. Pretherapy circulating IFN was significantly correlated with progressive Kaposi's sarcoma during therapy, but rises in levels of 2-5A synthetase were not sufficient to predict a good clinical response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993441     DOI: 10.1093/infdis/152.3.457

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

Review 2.  Cellular immunology of HIV-infection.

Authors:  G P Spickett; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

3.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

4.  Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.

Authors:  M G Brook; J A McDonald; P Karayiannis; L Caruso; G Forster; J R Harris; H C Thomas
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

5.  Detection of elevated levels of 2-5A synthetase in serum from children with various infectious diseases.

Authors:  H Sugino; I Mitani; M Koike; T Kodama; J Sokawa; H Sawai; K Ishibashi; M Itoh; S Watanabe; Y Sokawa
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

6.  Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA.

Authors:  D N SenGupta; R H Silverman
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

7.  Clinical significance of serum 2,5-oligoadenylate synthetase and soluble interleukin-2 receptor in hemophiliacs positive and negative for human immunodeficiency virus type 1.

Authors:  J Matsuda; M Gotoh; K Gohchi; M Tsukamoto; N Saitoh; T Kinoshita
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.